← All trials
NCT04910594
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Feb 14, 2023
- Completion date
- Apr 1, 2023
- First posted
- Jun 2, 2021
- Last posted
- Aug 11, 2021
- Enrollment
- 130
- Arms / groups
- — / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityCollaborator
- Zhejiang Chinese Medical UniversityCollaborator
- Wenzhou Medical UniversityCollaborator
- First People's Hospital of HangzhouCollaborator
- Wenzhou Medical UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
- Wenzhou Medical UniversityCollaborator
- Taizhou Hospital of Zhejiang ProvinceCollaborator
- Ningbo Medical Center Lihuili Eastern HospitalCollaborator
- Jiaxing Maternity and Child Health Care HospitalCollaborator
- Zhejiang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.